Literature DB >> 12228009

Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis.

Andreas Lundqvist1, Aniruddha Choudhury, Takako Nagata, Tove Andersson, Gary Quinn, Timothy Fong, Norman Maitland, Sven Pettersson, Staffan Paulie, Pavel Pisa.   

Abstract

The aim of this study was to examine the effect of two of the most commonly used viral vectors, that is, retrovirus and adenovirus, on the antigen presentation of dendritic cells (DCs). DCs were generated from CD34(+) hematopoietic precursors and CD14(+) monocytes of the same prostate cancer patients. Adenoviral transduction of monocyte-derived DCs (MO-DCs) resulted in upregulation of CD80, CD86, and CD83 expression. Adenovirus-transduced MO-DCs were also more potent stimulators of allogeneic lymphocytes, produced increased amounts of the cytokines tumor necrosis factor alpha and interleukin 12 p70, and exhibited increased expression of NF-kappaB and antiapoptotic molecules Bcl-X(L) and Bcl-2. Enhanced expression of the antiapoptotic molecules correlated with increased resistance of adenovirus-transduced MO-DCs to spontaneous as well as Fas-mediated cell death. In contrast to the adenoviral construct, no significant transduction of MO-DCs with the retrovirus could be obtained. Transduction of CD34(+) cell-derived DCs with the retrovirus or the adenovirus did not significantly alter expression of the costimulatory molecules or cytokines studied. At lower stimulation ratios, CD34(+) cell-derived DCs transduced with retrovirus were less potent in their ability to stimulate allogeneic lymphocytes in comparison with nontransduced DCs. Our results indicate that adenoviral vectors may be more suitable for gene delivery to DCs for immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228009     DOI: 10.1089/10430340260201635

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2.

Authors:  Allison T Thiele; Tina L Sumpter; Joanna A Walker; Qi Xu; Cheong-Hee Chang; Robert L Bacallao; Rajesh Kher; David S Wilkes
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  A synergistic antitumor effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma.

Authors:  Kinshi Kosaka; Masakazu Yashiro; Yoji Sakate; Kosei Hirakawa
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

3.  Regulation of Immune Responses by Spontaneous and T cell-mediated Dendritic Cell Death.

Authors:  Min Chen; Jin Wang
Journal:  J Clin Cell Immunol       Date:  2011-12-11

Review 4.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

5.  Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Authors:  Lazar Vujanovic; Theresa L Whiteside; Douglas M Potter; Jessica Chu; Soldano Ferrone; Lisa H Butterfield
Journal:  Cancer Immunol Immunother       Date:  2008-05-17       Impact factor: 6.968

Review 6.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

7.  Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses.

Authors:  Andreas Lundqvist; Andreas Palmborg; Gawa Bidla; Mike Whelan; Hardev Pandha; Pavel Pisa
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 8.  Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.

Authors:  Yu-Zhe Chen; Xing-Lei Yao; Yasuhiko Tabata; Shinsaku Nakagawa; Jian-Qing Gao
Journal:  Clin Dev Immunol       Date:  2010-12-20

9.  Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.

Authors:  Karen Riedl; Felicita Baratelli; Raj K Batra; Seok Chul Yang; Jie Luo; Brian Escuadro; Robert Figlin; Robert Strieter; Sherven Sharma; Steven Dubinett
Journal:  Mol Cancer       Date:  2003-11-02       Impact factor: 27.401

10.  Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.

Authors:  Felicita Baratelli; Hiroko Takedatsu; Saswati Hazra; Katherine Peebles; Jie Luo; Pam S Kurimoto; Gang Zeng; Raj K Batra; Sherven Sharma; Steven M Dubinett; Jay M Lee
Journal:  J Transl Med       Date:  2008-07-22       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.